Apollomics Inc. (NASDAQ:APLM) Short Interest Update

Apollomics Inc. (NASDAQ:APLM) was the target of a significant drop in short interest in May. As of May 29th, there was short interest totaling 1,592 shares, a drop of 51.2% from the May 14th total of 3,260 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average trading volume of 10,971 shares, the short-interest ratio is currently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC purchased a new stake in shares of Apollomics Inc. (NASDAQ:APLM) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.13% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Apollomics Stock Performance

Apollomics stock opened at $13.83 on Friday. Apollomics has a 1 year low of $3.66 and a 1 year high of $42.12. The firm’s 50 day moving average price is $14.27 and its two-hundred day moving average price is $17.17.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.